Back to Agenda
Session 7, Track C: Artificial Intelligence (AI) in Pharmacovigilance
Session Chair(s)
Vanessa Zapata
Associate Director, Regional Pharmacovigilance Officer, Merck Canada Inc., Canada
Nadia Latif, MS
Senior Manager, Pharmacovigilance, Ipsen Biopharmaceuticals Canada Inc., Canada
Agnes Jankowicz, MS
Vice President, Pharmacovigilance, ClaroPV Services Inc, Canada
The use of Artificial Intelligence (AI) in pharmacovigilance has been increasing significantly. Companies have demonstrated how AI can be used for processing high volumes of Adverse Events to improve efficiencies without adding any ressources while reducing the risk of human errors.
Learning Objective : At the conclusion of this session, participants should be able to:- Recognize when AI can be used for a specific task
- Assess if a specific task would be performed more efficiently by AI than by a person
- Integrate AI to pharmacovigilance systems and workflows
Speaker(s)
Suzanne Tracy, MBA
Head, Digital Innovation, PV Operations, Moderna, United States
Use of Digital Platform to Report Aes
Farheen Shaikh, MS
Director - Country Head, Pharmacovigilance, Canada, Moderna , Canada
Use of Digital Platform to Report Aes
Heather Ward, PHD, MS
Director, Safety Surveillance Research, Pfizer, Canada
Predictive Modeling to Enhance Real-World Data for Safety Studies: Atopic Dermatitis as a Case Study
Have an account?